Cargando…

Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs

SIMPLE SUMMARY: Natural Killer (NK) cells play a major role in cancer immunotherapy based on tumor-targeting mAbs. NK cell-mediated tumor cell killing and cytokine secretion are powerfully stimulated upon interaction with IgG-opsonized tumor cells, through the aggregation of FcγRIIIA/CD16 IgG recept...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capuano, Cristina, Pighi, Chiara, Battella, Simone, De Federicis, Davide, Galandrini, Ricciarda, Palmieri, Gabriella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161310/ https://www.ncbi.nlm.nih.gov/pubmed/34065399 http://dx.doi.org/10.3390/cancers13102500

Ejemplares similares

CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to γ(c) cytokine stimulation via PI3K/mTOR axis
por: Capuano, Cristina, et al.
Publicado: (2020)

Memory NK Cell Features Exploitable in Anticancer Immunotherapy
por: Capuano, Cristina, et al.
Publicado: (2019)

Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production
por: Capuano, Cristina, et al.
Publicado: (2017)

(Auto)Antibody Responses Shape Memory NK Cell Pool Size and Composition
por: Capuano, Cristina, et al.
Publicado: (2022)

Tumor-Targeting Anti-CD20 Antibodies Mediate In Vitro Expansion of Memory Natural Killer Cells: Impact of CD16 Affinity Ligation Conditions and In Vivo Priming
por: Capuano, Cristina, et al.
Publicado: (2018)

Impact of SARS-CoV-2 vaccination on FcγRIIIA/CD16 dynamics in Natural Killer cells: relevance for antibody-dependent functions
por: Capuano, Cristina, et al.
Publicado: (2023)

Activation of Lymphocyte Cytolytic Machinery: Where are We?
por: Galandrini, Ricciarda, et al.
Publicado: (2013)

SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023)

ISA-2011B, a Phosphatidylinositol 4-Phosphate 5-Kinase α Inhibitor, Impairs CD28-Dependent Costimulatory and Pro-inflammatory Signals in Human T Lymphocytes
por: Kunkl, Martina, et al.
Publicado: (2017)

Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition
por: Petillo, Sara, et al.
Publicado: (2021)

Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells
por: Passariello, Margherita, et al.
Publicado: (2020)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

The Different Colors of mAbs in Solution
por: Ambrogelly, Alexandre
Publicado: (2021)

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
por: Golay, Josée, et al.
Publicado: (2020)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival
por: Poli, Aurélie, et al.
Publicado: (2013)

Characterization of Two Novel mAbs Recognizing Different Epitopes on CD43
por: Kim, Soseul, et al.
Publicado: (2014)

Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs
por: Chenoweth, Alicia M, et al.
Publicado: (2020)

Glycosylation characterization of therapeutic mAbs by top- and middle-down mass spectrometry
por: Tran, Bao Quoc, et al.
Publicado: (2015)

WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed
por: Wu, Mary Y, et al.
Publicado: (2023)

Cellular tools for biosimilar mAb analysis
por: Lindemann, Carsten, et al.
Publicado: (2013)

Evolving trends in mAb production processes
por: Shukla, Abhinav A., et al.
Publicado: (2017)

State of the art in anti-cancer mAbs
por: Chiavenna, S. M., et al.
Publicado: (2017)

LPS combined with CD47mAb enhances the anti‑osteosarcoma ability of macrophages
por: Yuan, Peng, et al.
Publicado: (2023)

Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy
por: Oppenheim, D E, et al.
Publicado: (2014)

Combining NK cells and mAb9.2.27 to combat NG2-dependent and anti-inflammatory signals in glioblastoma
por: Kmiecik, Justyna, et al.
Publicado: (2014)

Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications
por: Piot, Numa, et al.
Publicado: (2021)

Stability enhancement in a mAb and Fab coformulation
por: Zhang, Hongyu, et al.
Publicado: (2020)

Pan-sarbecovirus mAb protects from variants
por: Flemming, Alexandra
Publicado: (2021)

A mAb for the detection of the antiretroviral drug emtricitabine
por: Youngpairoj, Ae S., et al.
Publicado: (2022)

Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
por: Zhang, Jingzhe, et al.
Publicado: (2019)

Complement system in Anti-CD20 mAb therapy for cancer: A mini-review
por: Gao, Yiwen
Publicado: (2023)

Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells
por: Snyder, Kristin M., et al.
Publicado: (2018)

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
por: André, Pascale, et al.
Publicado: (2018)

The therapeutic efficacy of I(131)-PSCA-mAb in orthotopic mouse models of prostate cancer
por: Yu, Shengqiang, et al.
Publicado: (2013)

Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets
por: de Wit, Emmie, et al.
Publicado: (2018)

Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era
por: Pecetta, Simone, et al.
Publicado: (2020)

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
por: Bolaños-Mateo, Elixabet, et al.
Publicado: (2014)

Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity
por: Li, Hua-Fei, et al.
Publicado: (2015)

Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma
por: Mohanty, Suchismita, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_36rlckder63tivcrbl78q9kcmq